The Latin America Minimal Residual Disease Market was valued at $51.6 Million in 2024 and projected to reach to $88.8 Million by 2029, representing a compound annual growth rate of 11.5%. Latin America's Minimal Residual Disease market is positioned for sustained expansion through 2029, driven by convergence of clinical demand and infrastructure development.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Latin America's MRD market is valued at $51.6 million in 2024, with a robust 11.5% CAGR projected through 2029, reaching $88.8 million. This growth trajectory reflects strong regional momentum in precision oncology diagnostics.
Increasing cancer prevalence across Latin America is driving demand for early detection and monitoring solutions. MRD testing enables clinicians to identify residual disease post-treatment, improving patient outcomes and treatment personalization.
Latin American countries are investing in advanced diagnostic capabilities and laboratory infrastructure. This modernization supports adoption of sophisticated MRD technologies and expands access to precision medicine across the region.
Growing adoption of next-generation sequencing, digital PCR, and flow cytometry platforms in Latin American healthcare facilities is accelerating MRD market penetration. Regional laboratories are increasingly integrating these advanced diagnostic methods into clinical practice.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | MULTIPLE MYELOMA (Application) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 12.2% from 2024 to 2029 |
| Largest Segment | ASSAY KITS & REAGENTS (Product) |
| Market Size Base Year (Billions) | ~USD 1.43 (2024) |
| Revenue Forecast (Billions) | ~USD 2.55 (2029) |
| Segments Covered | Product, Technology, Application, Type, End User |
5 segment dimensions are covered across the global market.
| Country | 2025 size (native) |
|---|
In Latin America, the Minimal Residual Disease market was valued at $51.6 million in 2024 and is projected to reach $88.8 million by 2029.
Latin America's MRD market is expected to grow at a compound annual growth rate (CAGR) of 11.5% from 2024 to 2029.
Latin America's MRD market growth is driven by increasing cancer incidence, adoption of precision oncology, expanding healthcare infrastructure, regulatory support for diagnostics, and rising healthcare expenditure.
In Latin America, MRD testing is primarily utilized in hematologic malignancies such as acute leukemia and lymphoma, as well as solid tumors including breast and colorectal cancers.
Latin America's healthcare systems are supporting MRD adoption through regulatory frameworks for companion diagnostics, increased healthcare investment, and partnerships between regional and international diagnostic providers.
This study involved four major activities in estimating the current size of the minimal residual disease testing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| Roche Ltd. | General Manager |
| Gaurdant | Area Sales Manager |
Both top-down and bottom-up approaches were used to estimate and validate the minimal residual disease testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The research methodology used to estimate the market size includes the following:

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Minimal Residual Disease (MRD) refers to the small number of cancer cells left in a body after cancer treatment. MRD tests are performed to diagnose and monitor patients with various hematology cancers, such as leukemia, lymphoma, and myeloma. An MRD test looks for cancer cells not killed by chemotherapy or other cancer treatments. Moreover, these tests also play a crucial role in clinical trials of hemato-oncology therapeutics.
Full forecast, segment splits, and company analysis for all Minimal Residual Disease Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report